Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA

Gene Therapy

Volumn 11, Issue 17, 2004, Pages 1331-1341

  Clawson, G A ^a   Miranda, G Q ^a,b   Sivarajah, A ^a   Xin, P ^a   Pan, W ^a   Thiboutot, D ^a   Christensen, N D ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antisense; DNAzyme; Human papillomavirus

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; LIPOSOME; MESSENGER RNA; NUCLEIC ACID; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; DEOXYRIBOZYME; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONDYLOMA; CONTROLLED STUDY; DNA LIBRARY; DRUG TARGETING; EMBRYO; GENE CONSTRUCT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSERVATION; PAPILLOMA; PREPUCE; PRIORITY JOURNAL; RNA ANALYSIS; STATISTICAL ANALYSIS; VIRUS INHIBITION; WART VIRUS; ANIMAL; CONDYLOMA ACUMINATUM; GENE THERAPY; GENETICS; METHODOLOGY; MOUSE MUTANT; PAPILLOMA VIRUS; SKIN TRANSPLANTATION; VIRUS INFECTION; XENOGRAFT;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRUS;

ANIMALS; CELLS, CULTURED; CONDYLOMATA ACUMINATA; DNA, CATALYTIC; GENE THERAPY; HUMANS; IN SITU HYBRIDIZATION; MALE; MICE; MICE, SCID; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; SKIN TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 4444221553     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302303     Document Type: Article

References (42)

1. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994; 186: 131-156.
2. Walboomers J et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Stoler MEA. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992; 23: 117-128.
4. Lancaster WEA. Human papillomavirus deoxyribonucleic acid in cervical carcinoma from primary and metastatic sites. Am J Obstet Gynecol 1986; 154: 115-119.
5. Howley P. Role of the human papillomaviruses in human cancer. Cancer Res 1991; 51: 5019s-5022s.
6. Howley P. Papillomavirinea: the viruses and their replication. In: Fields BDK, Howley P (eds). Virology. Lippencott-Raven: Philadelphia, 1996, p 2055.
7. Munger K, Scheffner M, Huibregtse J, Howley P. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992; 12: 197-217.
8. Slebos R et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci (USA) 1994; 91: 5320-5324.
9. Jones D, Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 1997; 71: 2905-2912.
10. Munoz N et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
11. Walboomers J, Meijer C. Do HPV-negative cervical carcinomas exist? (Editorial). J Pathol 1997; 181: 253-254.
12. Herrington C. Do HPV-negative cervical carcinomas exist? - revisited (Editorial; Comment). J Pathol 1999; 189: 1-3.
13. Durst M et al. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus (HPV) type 16 DNA. Oncogene 1987; 1: 251-256.
14. Barbosa M, Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989; 4: 1529-1532.
15. Meyers C, Harry J, Lin Y, Wettstein F. Identification of three transforming proteins encoded by cottontail rabbit papillomavirus. J Virol 1992; 66: 1655-1664.
16. Brandsma J, Yang Z, Barthold S, Johnson E. Use of a rapid, efficient inoculation method to induce papillomas by cottontail rabbit papillomavirus DNA. Proc Natl Acad Sci USA 1991; 88: 4816-4820.
17. Smotkin D, Prokoph H, Wettstein F. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol 1989; 63: 1441-1447.
18. Von Knebel Doeberitz M, Rittmuller C, zur Hansen H, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992; 51: 831-834.
19. Alvarez-Salas L, Arpawong T, DiPaolo J. Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene. Antisense Nucleic Acid Drug Dev 1999; 9: 441-450.
20. Chen Z et al. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther 1995; 2: 263-271.
21. Chou C et al. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol Oncol 2000; 78: 293-301.
22. Hamada K et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996; 63: 219-227.
23. Hu G et al. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papillomavirus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther 1995; 2: 19-32.
24. Huang Y et al. Stable expression of anti-HPV 16 E7-ribozyme in CV-1 cell lines. Chin J Biotechnol 1996; 12: 215-220.
25. Lappalainen K et al. Effects of liposomal antisense oligonucleotides on mRNA and protein levels of the HPVE7 oncogene. Anticancer Res 1996; 16: 2485-2492.
26. Lewis E et al. Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Res 2000; 48: 187-196.
27. Venturini F et al. Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: antiproliferative effects on HPV 16-transformed cells. Nucleic Acids Res 1999; 27: 1585-1592.
28. Pan W-H et al. A selection system for identifying accessible sites in target RNAs. RNA 2001; 7: 610-621.
29. Pan WH, Xin P, Bui V, Clawson G. Rapid Identification of efficient target cleavage sites using a hammerhead ribozyme library in an iterative manner. Mol Ther 2003; 7: 128-138.
30. Pan W, Xin P, Morrey J, Clawson G. A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol Ther 2004; 9: 596-606.
31. Templeton N et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotech 1997; 15: 647-652.
32. Kreider J et al. Laboratory production in vivo of infectious human papillomavirus type 11. J Virol 1987; 61: 590-593.
33. Christensen N, Kreider J, Shah K, Rando R. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992; 73: 1261-1267.
34. Christensen N et al. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64: 5678-5681.
35. Christensen N et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75: 2271-2276.
36. Christensen N et al. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 1994; 205: 329-335.
37. Beutner K et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-239.
38. Santiago FS et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999; 5: 1438-1441.
39. Pan W, Clawson G. Identification of efficient cleavage sites in long target RNAs. In: Sioud M (ed). Methods in Molecular Biology, Vol. 252: Ribozymes and siRNA Protocols, 2nd edn, Chapter 9, Humana Press: Totowa, NJ, 2004, pp 125-144.
40. Herasse M et al. Expression and functional characteristics of calpain 3 isoforms generated through tissue-specific transcriptional and posttranscriptional events. Mol Cell Biol 1999; 19: 4047-4055.
41. Pfaffl M, Horgan G, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
42. Lieb L et al. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro. J Pharm Sci 1997; 86: 1022-1029.